Panelists:
Jinpeng Li, PhD
Director
WuXi Testing-BAS
WuXi AppTec
Peng Li, PhD
Senior Scientist
WuXi Testing-DMPK
WuXi AppTec
Xiangyi Wang
Assistant Director
WuXi Biology
In Vivo Pharmacology Unit
- Time:
Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics. But their complex structure poses significant development and safety challenges for biopharma.
In this GEN webinar, experts from WuXi AppTec will share essential strategies and methodologies for accelerating pre-clinical assessments of ADCs. This will include approaches for assessing the pharmacology, biotransformation, toxicokinetics, and immunogenicity of biologics early in their development. The webinar will introduce a comprehensive approach for evaluating ADC efficacy that assesses both antibody-specific and payload-specific mechanisms through various multi-dimensional assays. It will also offer methods for addressing ADC resistance as well as for metabolite profiling and identifying payload-related species for cleavable and non-cleavable ADCs. Furthermore, comprehensive solutions for assessing toxicokinetics of ADCs will be discussed followed by immunogenicity and immunotoxicity evaluation approaches.
In this webinar you’ll learn:
- Research strategies for pre-clinical ADC pharmacological evaluation and overcoming ADC resistance
- The complex biotransformation processes of ADCs and detailed methodologies for metabolite profiling of payload-related species and Drug-to-Antibody Ratio distributions
- Comprehensive bioanalytical strategies for toxicokinetics, immunogenicity and immunotoxicity evaluation
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.
Produced with support from:
